A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, displays two doses of COVID-19 inactivated vaccine in prefilled syringes in Beijing, capital of China, Dec. 23, 2020. (Xinhua/Zhang Yuwei)

BEIJING, Feb. 6 -- China's National Medical Products Administration (NMPA) on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday.

The Sinovac vaccine, produced by the Beijing-based Sinovac Life Sciences Co. Ltd., affiliated with Sinovac Biotech, was approved for emergency use in China last June. The vaccine started being used for emergency inoculation among some special groups in the country from July last year.

From this January, countries including Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos successively approved the emergency use of the Sinovac vaccine locally.